Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
Receipt is acknowledged of the Information Disclosure Statement filed 15 December 2023. The Examiner has considered the reference cited therein to the extent that each is a proper citation. Please see the attached USPTO Form.
Election/Restrictions
Applicant's election without traverse of Group I (claims 1-8 and 19-20) in the reply filed on 14 October 2026 is acknowledged.
Claims 9-18 are cancelled and withdrawn from consideration from further consideration pursuant to 37 CFR 1.142(b), as being withdrawn to a non-elected invention, and non-elected species of the invention, there being no allowable generic or linking claims.
Claims 1-8 and 19-20 are under examination and the requirement for restriction is made final.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-7 and 19-20 are rejected under 35 U.S.C. 102(a)(1) and (a)(2) as being anticipated by Rueping et al. “Effective synthesis of 2,5-disubstituted tetrahydrofurans from glycerol by catalytic alkylation of ketones” (located in Information Disclosure Statement).
With regard to claims 1-7 and 19-20, Reuping et al. teaches the catalytic α-alkylation of acetophenone with solketal to produce a compound of the following structure (Table 1, page 56):
PNG
media_image1.png
177
359
media_image1.png
Greyscale
This compound meets all limitations of formula (I), wherein n is 0, X is an oxygen atom, R¹ and R² are each an alkyl group, R³ and R⁴ are each a hydrogen atom, and R⁵, R⁶, R⁷, and R⁸ are each a hydrogen atom.
Claims 1-7 and 19-20 are rejected under 35 U.S.C. 102(a)(1) and (a)(2) as being anticipated by Lan et al. “An iron-catalyzed hydro alkylation reaction of α,β-unsaturated ketones with ethers” (located in Information Disclosure Statement).
With regard to claims 1-7 and 19, Lan et al. teaches the hydro alkylation of vinyl ketones using catalyzed ethers to produce a compound of the following structure (Table 3, 3ard):
PNG
media_image2.png
104
232
media_image2.png
Greyscale
This compound meets all limitations of formula (I), wherein n is 0, X is an oxygen atom, R¹ and R², R5 are each an alkyl group, R³ and R⁴ are each a hydrogen atom, and R⁶, R⁷, and R⁸ are each a hydrogen atom.
With regard to claim 20, Lan et al. teaches the hydro alkylation of vinyl ketones using catalyzed ethers to produce a compound of the following structure (Table 3, 3ard):
PNG
media_image2.png
104
232
media_image2.png
Greyscale
This compound meets all limitations of formula (I), wherein n is 0, X is an oxygen atom, R¹ and R², R6 are each an alkyl group, R³ and R⁴ are each a hydrogen atom, and R5, R⁷, and R⁸ are each a hydrogen atom.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim 8 is rejected under 35 U.S.C. 103 as being unpatentable over Rueping et al. “Effective synthesis of 2,5-disubstituted tetrahydrofurans from glycerol by catalytic alkylation of ketones” (located in Information Disclosure Statement) as applied to claims 1-7 and 19-20 above, and further in view of Rueping et al.
With regard to claim 8, while Rueping et al. does not teach the specified compounds of formula (I). However, Reuping et al. teaches a homolog structure of 1-phenyl-3-(2-phenyl-1,3-dioxan-4-yl)propan-1-one (Table 1, page 56):
PNG
media_image1.png
177
359
media_image1.png
Greyscale
With regard to the homolog structure, the compound of Reuping et al. is a homolog differing regularly by the successive addition of the same chemical groups, in the present instance, a -CH3-group. Homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”. In re Wilder, 563 F.2D 457, 195 USPQ 426 (CCPA 1977). A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. “An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties.” In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 245 (CCPA 1979); MPEP 2144.09. It would have been obvious to one of ordinary skill in the art before the effective filling date of the claimed invention to modify Reuping et al.’s compound to arrive at the claimed invention of 1-phenyl-3-(2-phenyl-1,3-dioxan-4-yl)propan-1-one. Specifically, to modify to a straight chain comprising C1-C10 alkyl-compounds as homolog of compound of Reuping et al., as the compound is expected to possess similar properties and have similar utility relative to the claimed compounds.
Claim 8 is rejected under 35 U.S.C. 103 as being unpatentable over Lan et al. “An iron-catalyzed hydro alkylation reaction of α,β-unsaturated ketones with ethers” (located in Information Disclosure Statement) as applied to claims 1-7 and 19-20 above, and further in view of Lan et al.
With regard to claim 8, while Lan et al. does not teach the specified compounds of formula (I). However, Lan et al. teaches the hydro alkylation of vinyl ketones using catalyzed ethers to produce a compound of the following structure (Table 3, 3ard):
PNG
media_image2.png
104
232
media_image2.png
Greyscale
With regard to the homolog structure, the compound of Lan et al. is a homolog differing regularly by the successive addition of the same chemical groups, in the present instance, a -CH3-group. Homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”. In re Wilder, 563 F.2D 457, 195 USPQ 426 (CCPA 1977). A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. “An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties.” In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 245 (CCPA 1979); MPEP 2144.09. It would have been obvious to one of ordinary skill in the art before the effective filling date of the claimed invention to modify Lan et al.’s compound to arrive at the claimed invention of 1-phenyl-3-(2-phenyl-1,3-dioxan-4-yl)propan-1-one. Specifically, to modify to a straight chain comprising C1-C10 alkyl-compounds as homolog of compound of Lan et al., as the compound is expected to possess similar properties and have similar utility relative to the claimed compounds.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Aja A Walker whose telephone number is (571)272-0037. The examiner can normally be reached Monday - Friday 7-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Angela Brown-Pettigrew can be reached at 571-272-2817. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/A.A.W./Examiner, Art Unit 1761
/TANISHA DIGGS/Primary Examiner, Art Unit 1761 October 27, 2026